公开(公告)号：AU2011343642A1

公开(公告)日：2013-05-02

申请号：AU2011343642

申请日：2011-12-16

Applicant: VERTEX PHARMA

Inventor： CHARIFSON PAUL S ,  CLARK MICHAEL P ,  BANDARAGE UPUL K ,  DAVIES IOANA ,  DUFFY JOHN P ,  GAO HUAI ,  FENG JUN ,  LIANG JIANGLIN ,  KENNEDY JOSEPH M ,  LEDEBOER MARK W ,  LEDFORD BRIAN ,  MALTAIS FRANCOIS ,  PEROLA EMANUELE

IPC: C07D471/04 ,  A61K31/16

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

公开(公告)号：CA2822057A1

公开(公告)日：2012-06-21

申请号：CA2822057

申请日：2011-12-16

Applicant: VERTEX PHARMA

Inventor： CHARIFSON PAUL S ,  CLARK MICHAEL P ,  BANDARAGE UPUL K ,  DAVIES IOANA ,  DUFFY JOHN P ,  GAO HUAI ,  FENG JUN ,  LIANG JIANGLIN ,  KENNEDY JOSEPH M ,  LEDEBOER MARK W ,  LEDFORD BRIAN ,  MALTAIS FRANCOIS ,  PEROLA EMANUELE

IPC: C07D471/04 ,  A61K31/16

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.